These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36909163)
1. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C Front Pharmacol; 2023; 14():1150774. PubMed ID: 36909163 [TBL] [Abstract][Full Text] [Related]
2. NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties. Wang LL; Wan XY; Liu CQ; Zheng FM Mol Med; 2022 May; 28(1):49. PubMed ID: 35508987 [TBL] [Abstract][Full Text] [Related]
3. ASR490, a Small Molecule, Overrides Aberrant Expression of Tyagi A; Chandrasekaran B; Kolluru V; Baby BV; Sripathi CA; Ankem MK; Ramisetti SR; Chirasani VR; Dokholyan NV; Sharma AK; Damodaran C Mol Cancer Ther; 2020 Dec; 19(12):2422-2431. PubMed ID: 33087513 [No Abstract] [Full Text] [Related]
4. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells. Kim SL; Choi HS; Lee DS Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094 [TBL] [Abstract][Full Text] [Related]
5. Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C Front Pharmacol; 2024; 15():1420266. PubMed ID: 38860169 [TBL] [Abstract][Full Text] [Related]
6. Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C Front Pharmacol; 2023; 14():1207589. PubMed ID: 37205914 [TBL] [Abstract][Full Text] [Related]
7. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564 [TBL] [Abstract][Full Text] [Related]
8. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer. So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438 [TBL] [Abstract][Full Text] [Related]
9. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Suman S; Das TP; Damodaran C Br J Cancer; 2013 Nov; 109(10):2587-96. PubMed ID: 24129237 [TBL] [Abstract][Full Text] [Related]
10. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097 [TBL] [Abstract][Full Text] [Related]
11. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB. Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707 [TBL] [Abstract][Full Text] [Related]
12. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2. Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735 [TBL] [Abstract][Full Text] [Related]
14. Sinomenine hydrochloride suppresses the stemness of breast cancer stem cells by inhibiting Wnt signaling pathway through down-regulation of WNT10B. Li X; Chen W; Huang L; Zhu M; Zhang H; Si Y; Li H; Luo Q; Yu B Pharmacol Res; 2022 May; 179():106222. PubMed ID: 35413424 [TBL] [Abstract][Full Text] [Related]
15. β1,4-Galactosyltransferase V Modulates Breast Cancer Stem Cells through Wnt/β-catenin Signaling Pathway. Tang W; Li M; Qi X; Li J Cancer Res Treat; 2020 Oct; 52(4):1084-1102. PubMed ID: 32599982 [TBL] [Abstract][Full Text] [Related]
16. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069 [TBL] [Abstract][Full Text] [Related]
17. Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients. Zekri AN; Bahnassy A; Mourad M; Malash I; Ahmed O; Abdellateif MS Cancer Cell Int; 2022 Dec; 22(1):423. PubMed ID: 36585652 [TBL] [Abstract][Full Text] [Related]
18. Lentivirus-mediated shRNA targeting Nanog inhibits cell proliferation and attenuates cancer stem cell activities in breast cancer. Hu C; Xu L; Liang S; Zhang Z; Zhang Y; Zhang F J Drug Target; 2016; 24(5):422-32. PubMed ID: 26339994 [TBL] [Abstract][Full Text] [Related]
19. ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44 Chen J; Liu S; Su Y; Zhang X Transl Cancer Res; 2020 Mar; 9(3):1652-1659. PubMed ID: 35117513 [TBL] [Abstract][Full Text] [Related]
20. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]